Biotech Values

[vinmantoo]

IMGN is up some 25% today on its earnings report with better than expected of sales of Elahere, their anti-Ovarian cancer ADC. The confirmatory phase 3 MIRASOL trial reached its pre-specified PFS number so results are expected in mid-May. Positive results should lead to full approval for Elahere. Looks like the IMGN turtle is finally approaching the finish line.

https://www.fool.com/investing/2023/04/28/why-shares-of-immunogen-jumped-friday/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

Elahere sales from Q1, the first full quarter after approval were $29.2 million. Full year guidance will come in the second half of 2023. If the MIRASOL data is good and leads to full approval in the US and the EU, that sales figures will have to be revised next year.

https://finance.yahoo.com/news/immunogen-reports-recent-progress-first-103000648.html